These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37951806)

  • 1. Tumor-to-blood pool ratio of 18F-fluorodeoxyglucose-positron emission tomography's standardized uptake value as a useful parameter indicating malignant transformation in pancreatic branch-duct intraductal papillary mucinous neoplasm compared to the international Fukuoka guidelines: a retrospective cohort study from surgical resections.
    Suto H; Ando Y; Matsukawa H; Oshima M; Kamada H; Kobara H; Masaki T; Tanaka K; Norikane T; Nishiyama Y; Hirao T; Kumamoto K; Okano K
    HPB (Oxford); 2024 Feb; 26(2):291-298. PubMed ID: 37951806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison with surgically resected mucinous cystic neoplasm of pancreas and branch-duct type intraductal papillary mucinous neoplasm considering clinico-radiological high-risk features: a reassessment of current guidelines.
    Kim H; Kim JH; An J; Choi JS
    Abdom Radiol (NY); 2024 Aug; 49(8):2746-2755. PubMed ID: 38744705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
    Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
    Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
    Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
    Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm?
    Roch AM; Barron MR; Tann M; Sandrasegar K; Hannaford KN; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2015 Jul; 221(1):48-56. PubMed ID: 26095551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?
    Niiya F; Ohike N; Norose T; Takano Y; Azami T; Kobayashi T; Maruoka N; Wakabayashi T; Matsuo K; Tanaka K; Nagahama M
    Pancreatology; 2020 Oct; 20(7):1379-1385. PubMed ID: 32873485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of the utility of 18-FDG PET in the preoperative evaluation of IPMNs and cystic lesions of the pancreas.
    Srinivasan N; Koh YX; Goh BKP
    Surgery; 2019 May; 165(5):929-937. PubMed ID: 30577952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical FAP Expression Reflects
    Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
    J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
    Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
    Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
    Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
    Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant transformation of branch duct-type intraductal papillary mucinous neoplasms of the pancreas based on contrast-enhanced endoscopic ultrasonography morphological changes: focus on malignant transformation of intraductal papillary mucinous neoplasm itself.
    Ohno E; Itoh A; Kawashima H; Ishikawa T; Matsubara H; Itoh Y; Nakamura Y; Hiramatsu T; Nakamura M; Miyahara R; Ohmiya N; Ishigami M; Katano Y; Goto H; Hirooka Y
    Pancreas; 2012 Aug; 41(6):855-62. PubMed ID: 22481289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mural nodule in branch duct-type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery.
    Akita H; Takeda Y; Hoshino H; Wada H; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Mori M; Doki Y; Nagano H
    Am J Surg; 2011 Aug; 202(2):214-9. PubMed ID: 21376305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT findings and clinical effects of high grade pancreatic intraepithelial neoplasia in patients with intraductal papillary mucinous neoplasms.
    Kim MC; Kim JH; Jeon SK; Kang HJ
    PLoS One; 2024; 19(4):e0298278. PubMed ID: 38683769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.